All the cells in the body—healthy and cancerous—have HER2 receptors. But HER2+ breast cancer cells have too many HER2 receptors, which makes them grow and divide faster than other types of cells. This causes tumors to form.
Your doctor will know that your breast cancer is HER2+ by ordering a HER2 test. This test should be done before any breast cancer treatment is started. PHESGO has been shown to work only in people with HER2+ breast cancer.
You might have been told you have early breast cancer or metastatic breast cancer. You may even have experience with both.
If you have early breast cancer, that means the cancer started in the breast and has not spread to other parts of the body. However, cancer cells may also be in nearby glands called lymph nodes.
Metastatic breast cancer means the cancer has spread to other parts of the body, such as the lungs, liver, or bones.
PHESGO can be used for both early and metastatic, but each has a different treatment plan.
Not all HER2+ breast cancers are the same. Before recommending a treatment plan for you, your healthcare team will consider a number of other factors about your particular cancer, as well as your personal medical history and condition. This is because some treatments are more appropriate for different patients. Here are some of the things your healthcare team will look at:
PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:
PHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
PHESGO may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).
Receiving PHESGO during pregnancy can result in the death of an unborn baby and birth defects.
PHESGO may cause serious lung problems.
The most common side effects of PHESGO when given with chemotherapy as part of an early breast cancer regimen are:
The most common side effects of PHESGO when given with docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PHESGO.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit phesgo.com/financial-support for financial assistance information.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.